Back to results
US 6,472,374 B1Granted
Endometrial function
AssigneeCambridge University Technical Services Limited
InventorsDavid Stephen Charnock-Jones, Stephen Kevin Smith, Andrew Mark Sharkey, Robert Brian Heap
Life of this patent
Estimating the term…
Abstract
Disclosed is a method of altering one or more characteristics of at least some of the cells of the reproductive tract of a mammalian individual by the introduction into said cells of a nucleic acid, together with a composition comprising nucleic acid, for use in the method.
Claims10
A method of transfecting uterine epithelial cells of a human in vivo comprising:
- a) providing a composition comprising a vector comprising a nucleic acid sequence encoding a protein operatively linked to a promoter;
- b) administering the composition into the lumen of a uterus in a human in vivo, wherein the composition is administered following ovulation of the human but before or during the peak in the level of progesterone in the blood of the human within the same reproductive cycle;
- and
- c) obtaining detectable expression of the protein in at least some uterine epithelial cells of the human.
1 more element
A method of transfecting uterine endometrial cells of a mammal in vivo comprising:
- a) providing a composition comprising a vector comprising a nucleic acid sequence encoding a protein operatively linked to a promoter;
- b) administering the composition into the lumen of a uterus in a mammal in vivo, wherein the composition is administered following ovulation of the mammal but before or during the peak in the level of progesterone in the blood of the mammal within the same reproductive cycle;
- and
- c) obtaining detectable expression of the protein in at least some uterine endometrial cells of the mammal.
1 more element
A method of transfecting uterine epithelial cells of a mammal in vivo comprising:
- a) providing a composition comprising a plasmid comprising a nucleic acid sequence encoding a protein operatively linked to a promoter, wherein the concentration of the plasmid is at least 1 μg/ml;
- b) administering the composition into the lumen of a uterus in a mammal in vivo, wherein the composition is administered following ovulation of the mammal but before or during the peak in the level of progesterone in the blood of the mammal within the same reproductive cycle;
- and
- c) obtaining detectable expression of the protein in at least some uterine endometrial cells of the mammal.
1 more element
Dependencies are inferred from the claim text.